Rice Hall James & Associates LLC Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Rice Hall James & Associates LLC raised its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 46.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,010,104 shares of the biopharmaceutical company's stock after acquiring an additional 639,024 shares during the period. Rice Hall James & Associates LLC owned about 0.65% of Amicus Therapeutics worth $16,402,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its holdings in shares of Amicus Therapeutics by 53.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 24,530 shares of the biopharmaceutical company's stock worth $195,000 after purchasing an additional 8,567 shares during the last quarter. Intech Investment Management LLC grew its holdings in shares of Amicus Therapeutics by 59.7% in the fourth quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company's stock worth $1,175,000 after purchasing an additional 46,633 shares during the last quarter. Norges Bank bought a new position in shares of Amicus Therapeutics in the fourth quarter worth approximately $29,033,000. Renaissance Technologies LLC grew its holdings in shares of Amicus Therapeutics by 174.1% in the fourth quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company's stock worth $19,863,000 after purchasing an additional 1,339,316 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Amicus Therapeutics by 35.7% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 302,536 shares of the biopharmaceutical company's stock worth $2,850,000 after purchasing an additional 79,602 shares during the last quarter.

Amicus Therapeutics Stock Up 3.6%

Amicus Therapeutics stock traded up $0.22 on Thursday, hitting $6.29. 5,224,185 shares of the stock traded hands, compared to its average volume of 3,239,513. The company has a current ratio of 3.34, a quick ratio of 2.47 and a debt-to-equity ratio of 2.02. The firm has a market cap of $1.94 billion, a P/E ratio of -69.88 and a beta of 0.51. The business's fifty day simple moving average is $6.07 and its 200 day simple moving average is $7.69. Amicus Therapeutics, Inc. has a 1 year low of $5.51 and a 1 year high of $12.65.

Wall Street Analysts Forecast Growth

FOLD has been the topic of several recent analyst reports. The Goldman Sachs Group cut their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Wall Street Zen lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. UBS Group raised their price target on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Finally, Morgan Stanley raised Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Amicus Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.